Asaf 200 mg
Sparfloxacin
Category: Tablet
Manufacturer: Asiatic Laboratories Ltd.
Allopathic
MFG. Licence No. Biological
069
MFG. Licence No. Non-Biological
151
Address
Tongi I/A, Gazipur
Price: 16.88 ৳
Tablet
Medicine Selling service is not available yet.
Related Medicines
Uses of Asaf:
- Bacterial infections
Chronic bronchitis, Community-acquired pneumonia
Hypersensitivity; pregnancy and lactation; children <18 yr.
4-Quinolone preparations
Sparfloxacin is a synthetic, broad-spectrum antibacterial agent from the difluoroquinolone family. It has been reported to be more active in vitro than ciprofloxacin against some organisms, including staphylococci and Mycobacteria, and has a much longer plasma half-life (16 hours).Sparfloxacin inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
How to use
Sparfloxacin:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.
Sparfloxacin may be taken with or without food, but it is better to take it at a fixed time.
Administration:
May be taken with or without food.
Adult Dose:
Oral
Adult
2 tablets (400 mg) on 1st day as a loading dose, followed by 1 tablet (200 mg) daily as a maintenance dose.
Duration of maintenance treatment is 10 days.
Renal Dose:
Renal impairment (Creatinine clearance < 50 ml/min) is 2 tablets (400 mg) taken on the first day as a loading dose. Thereafter, 1 tablet of 200 mg should be taken every 48 hours for total 9 days of therapy.
Cations such as aluminum, magnesium, zinc and iron may reduce the bioavailability of sparfloxacin. May increase the plasma concentrations of theophylline and tizanidine. May enhance the effect of warfarin and glibenclamide. May decrease the renal clearance of methotrexate. Excretion may be reduced by probenecid. May alter serum levels of phenytoin.
Potentially Fatal: Corticosteroids may increase risk of tendon rupture. Increased risk of seizures with NSAIDs. Risk of additive QT prolongation effect when used with class Ia or III antiarrhythmic drugs, astemizole, terfenadine, cisapride, erythromycin, pentamidine, phenothiazines or TCAs.
Hypersensitivity; pregnancy and lactation; children <18 yr.
Common
- Dizziness
- Stomach pain
- Nausea
- Bitter taste
- Indigestion
- Diarrhea
Diarrhoea, abdominal pain, nausea, vomiting; jaundice, renal failure, elevation of liver enzymes, BUN and creatinine; anaphylactoid reaction, headache, dizziness, convulsions; tremors, myalgia; rhabdomyolysis, thrombocytopenia and eosinophilia.
Potentially Fatal: AV block; anaphylaxis.
There are no adequate and well controlled studies in pregnant women. Sparfloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Precaution:
History of CNS disorders, pseudomembranous colitis, superinfection, severe renal dysfunction, epilepsy, G6PD deficiency, myasthenia gravis, patients with QT prolongation, uncorrected electrolyte disturbances, bradycardia, or pre-existing cardiac disease. Avoid exposure to strong sunlight or sunlamps during treatment. Discontinue treatment if patients experience tendon pain, inflammation or rupture; subsequent use of fluoroquinolones in these patients is not recommended. Avoid in MRSA infections due to high risk of resistance. Ensure adequate fluid intake to reduce risk of crystalluria.
To store this medicine it should be kept out of the reach of children. Stored away from heat and direct light. Stored below 30ºC.
4-Quinolone preparations
Sparfloxacin inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
There are no adequate and well controlled studies in pregnant women. Sparfloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Samm Care